Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Four Patent Applications Related to RNAi: Jan 31, 2008

Title: Compositions and Methods for Inhibiting Expression of Huntingtin Gene
Number: 7,320,965
Filed: Oct. 27, 2006
Lead Inventor: Dinah Wen-Yee Sah, Alnylam Pharmaceuticals
The patent, its abstract states, “relates to a double-stranded ribonucleic acid for inhibiting the expression of the Huntingtin gene, comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.”

Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules
Number: 20080020058
Filed: Oct. 24, 2006
Lead Inventor: Tongqian Chen, Sirna Therapeutics (Merck)
The invention, the patent application’s abstract states, “relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity in a subject or organism. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles, and transfection agents that effectively transfect or deliver biologically active molecules such as … short interfering nucleic acid … to relevant cells and/or tissues, such as in a subject or organism,” the abstract adds. “Such novel cationic lipids, microparticles, nanoparticles, and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject, or organism. The compositions described herein are generally referred to as formulated molecular compositions or lipid nanoparticles.”

Title: Oligo Double-Stranded RNA Inhibiting the Expression of Bcl-2 and Pharmaceutical Compositions Containing the Same
Number: 20080020990
Filed: May 28, 2004 PCT Filed: May 28, 2004
Lead Inventor: Junichi Yano, Nippon Shinyaku Co.
According to the patent application’s abstract, the invention relates to “oligo double-stranded RNAs for use in knockdown of the expression of Bcl-2 protein known as a suppressor for apoptosis, and pharmaceutical compositions containing them. It is known that Bcl-2 protein is over-expressed in diseases such as cancer, and by this over-expression, the growth of cancer cells is continued and the drug resistance to anti-cancer agents is caused. The … invention provides highly active oligo double-stranded RNAs cleaving bcl-2 mRNA and further provides pharmaceutical compositions comprising a complex of the oligo double-stranded RNA and a suitable carrier for inhibiting the expression of Bcl-2 protein.”

Title: Multicistronic Constructs with siRNA to Inhibit Tumors
Number: 20080020992
Filed: May 15, 2007
Lead Inventor: Jasti Rao, University of Illinois
The patent application, according to its abstract, claims “multicistronic short interfering RNA constructs targeting in various combinations a human urokinase-type plasminogen activator receptor, human urokinase-type plasminogen activator, human matrix metalloprotease 9, and cathepsin B.”

Title: In Planta RNAi Control of Fungi
Number: 20080022423
Filed: Feb. 1, 2007
Lead Inventor: James Roberts, Monsanto
The invention, the patent application’s abstract states, “relates to control of fungal and oomycete plant pathogens by inhibiting one or more biological functions. The invention provides methods and compositions for such control. By feeding one or more recombinant double-stranded RNA molecules provided by the invention to the pathogen, a reduction in disease may be obtained through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic agents for use in protecting plants from pathogen infection.”

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.